Dyadic International (DYAI) Stock Price, Quote & News

Company Profile

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large...

Industry: Biotechnology

Sector: Healthcare

Phone: 561 743 8333

Fax: 561 743 8343

Website: www.dyadic.com

Address:

1044 North U.S. Highway One, Suite 201, Jupiter, United States

STOCKSGambino May. 8 at 10:12 PM

$DYAI https://x.com/StocksGambino/status/2052874086657749150

0 · Reply

STOCKSGambino May. 8 at 9:19 PM

$DYAI https://x.com/StocksGambino/status/2052858547290189961

0 · Reply

STOCKSGambino May. 8 at 5:56 PM

$DYAI https://x.com/StocksGambino/status/2052809825071854011

0 · Reply

SmallCapGrowth May. 7 at 6:21 PM

$DYAI — Dyadic Applied BioSolutions - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6828424

0 · Reply

SmallCapGrowth May. 7 at 3:50 PM

$DYAI #NASDAQ The Engine of Innovation: Dyadic and Proliant’s Commercial Breakthrough https://www.youtube.com/watch?v=AFbJ_3uuzLU&t=20s #DYAI #Biotech #StockAlert #Investing @thebullrunshow

0 · Reply

SmallCapGrowth May. 7 at 2:45 PM

MOMO'S BREAKOUT BOARD : 🚨 $DYAI — Dyadic Applied BioSolu... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177579328 via @Investors_Hub

0 · Reply

SmallCapGrowth May. 7 at 1:12 PM

🚨 $DYAI — Dyadic Applied BioSolutions is accelerating commercial momentum with product launches and new partnerships. Quick 2-min read: https://wix.to/W5vEilH #DYAI #Biotech #StockAlert #Investing @thebullrunshow

0 · Reply

Thebullrun May. 6 at 11:47 AM

$DYAI $NVAX

2 · Reply

SmallCapGrowth May. 5 at 5:46 PM

$DYAI Alert: Dyadic Applied BioSolutions - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6828053

0 · Reply

SmallCapGrowth May. 5 at 3:31 PM

🚨 $DYAI Alert: Dyadic Applied BioSolutions is building a commercial catalyst stack — new launches, partnerships, and momentum toward product revenue. Read more: https://wix.to/yoHNqJp #DYAI #Biotech #DNA #nvax #cdxs @thebullrunshow

0 · Reply

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

Mar 25, 2026, 5:00 PM EDT - 6 weeks ago

Dyadic International Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:51 PM EDT - 6 weeks ago

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

2026-03-16T11:36:49.000Z - 7 weeks ago

Dyadic International enter distribution partnership with IBT Bioservices

Mar 16, 2026, 7:20 AM EDT - 7 weeks ago

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Mar 12, 2026, 1:30 PM EDT - 2 months ago

Dyadic International Transcript: Life Sciences Virtual Investor Forum

Mar 11, 2026, 4:10 PM EDT - 2 months ago

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

2026-03-04T12:23:22.000Z - 2 months ago

Dyadic International, Fermbox Bio launch of RNase-Free

Mar 4, 2026, 7:20 AM EST - 2 months ago

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

2026-03-02T12:33:34.000Z - 2 months ago

Dyadic International, Inzymes announce planned 2026 commercialization

2026-03-02T12:29:56.000Z - 2 months ago

Dyadic International, Inzymes announce planned 2026 commercialization

Mar 2, 2026, 7:20 AM EST - 2 months ago

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Feb 17, 2026, 7:25 AM EST - 2 months ago

Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

2025-12-17T12:26:09.000Z - 5 months ago

Dyadic International, Fermbox Bio expand strategic collaboration

2025-12-15T12:25:44.000Z - 5 months ago

Dyadic International establishes commercial partnership with Opes

Dec 15, 2025, 7:20 AM EST - 5 months ago

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins

Dec 9, 2025, 9:30 AM EST - 5 months ago

Dyadic International Transcript: IAccess Alpha Virtual MicroCap Conference

Dec 1, 2025, 7:25 AM EST - 5 months ago

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

2025-11-12T22:30:23.000Z - 6 months ago

Dyadic International reports Q3 EPS (6c), consensus (4c)

Nov 12, 2025, 5:00 PM EST - 6 months ago

Dyadic International Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:05 PM EST - 6 months ago

Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

2025-11-10T12:38:06.000Z - 6 months ago

Dyadic International, ERS Genomics announces CRISPR/Cas9 license

Oct 29, 2025, 7:25 AM EDT - 6 months ago

Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

2025-10-23T10:10:55.000Z - 7 months ago

Dyadic International assumed with a Buy at H.C. Wainwright

2025-10-06T12:50:17.000Z - 7 months ago

Dyadic International announces achievement of milestone payments

Oct 6, 2025, 8:30 AM EDT - 7 months ago

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

Sep 18, 2025, 9:15 AM EDT - 8 months ago

Dyadic International Transcript: Small-Cap Virtual Conference

2025-09-08T13:20:27.000Z - 8 months ago

Craig-Hallum bullish on Dyadic International, initiates with a Buy

2025-09-08T11:20:43.000Z - 8 months ago

Dyadic International initiated with a Buy at Craig-Hallum

Sep 4, 2025, 9:00 AM EDT - 8 months ago

Dyadic to Present at Investor Conferences and BPI East

Aug 13, 2025, 5:00 PM EDT - 9 months ago

Dyadic International Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:01 PM EDT - 9 months ago

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Aug 5, 2025, 4:11 PM EDT - 9 months ago

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

2025-07-31T12:50:32.000Z - 10 months ago

Dyadic International prices 6.05M shares at 95c in underwritten public offering

Jul 31, 2025, 8:47 AM EDT - 10 months ago

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

2025-07-31T11:41:14.000Z - 10 months ago

Dyadic International prices 6.05M shares in underwritten public offering

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

2025-07-30T20:13:50.000Z - 10 months ago

Dyadic International announces common stock offering, no amount given

Jul 30, 2025, 4:02 PM EDT - 10 months ago

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

2025-07-02T20:05:15.000Z - 11 months ago

Dyadic International rebrands as Dyadic Applied BioSolutions

Jul 2, 2025, 4:00 PM EDT - 11 months ago

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

2025-06-02T12:45:52.000Z - 1 year ago

Dyadic International names Joe Hazelton as President

Jun 2, 2025, 8:35 AM EDT - 1 year ago

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

May 14, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings Call Transcript: Q1 2025

May 1, 2025, 3:00 PM EDT - 1 year ago

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Apr 16, 2025, 2:00 PM EDT - 1 year ago

Dyadic to Present at World Vaccine Congress | Washington

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings Call Transcript: Q4 2024

2025-03-26T20:15:40.000Z - 1 year ago

Dyadic International files to sell 840K shares of common stock for holders

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Dyadic Reports 2024 Year-End Financial Results and Business Updates

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

Mar 6, 2025, 8:30 AM EST - 1 year ago

Dyadic to Attend Multiple Industry Events in March

Jan 6, 2025, 8:30 AM EST - 1 year ago

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Nov 21, 2024, 8:30 AM EST - 1 year ago

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Nov 12, 2024, 5:00 PM EST - 1 year ago

Dyadic International Earnings Call Transcript: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Dyadic Expands Global Presence with Participation in Key Industry Events

Sep 23, 2024, 9:50 AM EDT - 1 year ago

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

Aug 13, 2024, 5:00 PM EDT - 1 year ago

Dyadic International Earnings Call Transcript: Q2 2024

Jul 30, 2024, 4:00 PM EDT - 1 year ago

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Jun 28, 2024, 8:30 AM EDT - 2 years ago

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

May 30, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Attend Industry Events in June

May 14, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings Call Transcript: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 8, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Industry and Investor Events in May

Apr 30, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Mar 28, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Change in Board and Management Leadership Roles

Mar 27, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Industry Events in April

Mar 26, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Mar 21, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

Mar 14, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

Mar 11, 2024, 9:57 AM EDT - 2 years ago

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 11, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 1, 2024, 8:30 AM EST - 2 years ago

Dyadic to Attend Industry Events in March

Feb 28, 2024, 8:30 AM EST - 2 years ago

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Feb 23, 2024, 2:00 AM EST - 2 years ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 21, 2024, 8:30 AM EST - 2 years ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 13, 2024, 8:30 AM EST - 2 years ago

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Feb 6, 2024, 8:30 AM EST - 2 years ago

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

STOCKSGambino May. 8 at 10:12 PM

$DYAI https://x.com/StocksGambino/status/2052874086657749150

0 · Reply

STOCKSGambino May. 8 at 9:19 PM

$DYAI https://x.com/StocksGambino/status/2052858547290189961

0 · Reply

STOCKSGambino May. 8 at 5:56 PM

$DYAI https://x.com/StocksGambino/status/2052809825071854011

0 · Reply

SmallCapGrowth May. 7 at 6:21 PM

$DYAI — Dyadic Applied BioSolutions - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6828424

0 · Reply

SmallCapGrowth May. 7 at 3:50 PM

$DYAI #NASDAQ The Engine of Innovation: Dyadic and Proliant’s Commercial Breakthrough https://www.youtube.com/watch?v=AFbJ_3uuzLU&t=20s #DYAI #Biotech #StockAlert #Investing @thebullrunshow

0 · Reply

SmallCapGrowth May. 7 at 2:45 PM

MOMO'S BREAKOUT BOARD : 🚨 $DYAI — Dyadic Applied BioSolu... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177579328 via @Investors_Hub

0 · Reply

SmallCapGrowth May. 7 at 1:12 PM

0 · Reply

Thebullrun May. 6 at 11:47 AM

$DYAI $NVAX

2 · Reply

SmallCapGrowth May. 5 at 5:46 PM

$DYAI Alert: Dyadic Applied BioSolutions - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6828053

0 · Reply

SmallCapGrowth May. 5 at 3:31 PM

0 · Reply

SmallCapGrowth May. 5 at 2:54 PM

0 · Reply

SmallCapGrowth May. 5 at 2:48 PM

MOMO'S BREAKOUT BOARD : 🚨 $DYAI Alert: Dyadic Applied Bi... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177571204 via @Investors_Hub @TheBullRunShow

0 · Reply

MikeTechnician May. 5 at 2:33 PM

$DYAI

1 · Reply

SmallCapGrowth May. 5 at 1:47 PM

🚨 $DYAI Alert: Dyadic Applied BioSolutions is building a commercial catalyst stack — new launches, partnerships, and momentum toward product revenue. Quick read on what’s driving the move: https://wix.to/yoHNqJp #DYAI #Biotech #DNA #nvax #cdxs @thebullrunshow

0 · Reply

SmallCapGrowth May. 5 at 1:34 PM

0 · Reply

WallStreetSignals May. 5 at 1:22 PM

$DYAI Dyadic International Inc. is driving the change to unlock scale, access, and impact for a sustainable global economy. https://dyadic.com/ #TheBullRunShow #DYAI $VRME $VMAR #VISL #DNA #NVAX #CDXS #SustainableFuture #GlobalImpact #DyadicInternational #FeedFuelHeal

0 · Reply

Thebullrun May. 5 at 1:04 PM

$NVAX Why #DYAI beats #DNA, #NVAX & #CDXS right now. $DYAI’s C1 fungal + Dapibus™ platform delivers faster, cheaper, higher-yield recombinant proteins vs. traditional mammalian/insect systems. Quick cell lines, animal-free, low-cost media — perfect for vaccines, enzymes, and biologics. Quick Edge: • $DNA Ginkgo Broad synthetic bio foundry with heavy cash burn and declining revenue.High capex, less focused efficiency$NVAX: Protein vaccines stuck in cyclical demand shifting to licensing after post-COVID revenue drop. Not a broad scalable platform $CDXS: Strong enzyme engineering but narrower scope — not built for full high-volume protein expression like DYAI DYAI is executing a commercial pivot Recent launches (e.g., recombinant albumin AlbuFree DX dairy enzyme deals targeting 2026 revenue plus grants/partnerships Tiny~$28M market cap with real product momentum and runway a world needing affordable rapid biologics DYAI’s tech moat + valuation asymmetry wins DYOR Not financial advice

0 · Reply

Thebullrun May. 5 at 12:00 PM

$CDXS if you like CDXS you’ll love $DYAI

0 · Reply

Thebullrun May. 5 at 11:58 AM

$DNA if you like DNA you’ll love $DYAI

0 · Reply

Thebullrun May. 5 at 11:57 AM

$NVAX if you like NVAX you’ll love $DYAI

1 · Reply

WallStreetSignals May. 4 at 4:47 PM

Make sure to keep Dyadic International Inc. (NASDAQ: $DYAI ) on your radar and capitalize on every chance to stay updated about the stock! For the latest insights and developments, visit https://dyadic.com/ today. #TheBullRunShow #DYAI $VISL $VMAR $TAAG #Investing #StockMarket #Finance #NASDAQ

0 · Reply

TheRealShortSqueezy May. 4 at 4:03 PM

$CELZ : Momentum Building as Breakthrough Data Fuels Renewed Interest 🧬 Creative Medical Technology Holdings is gaining attention after its April 28 breakthrough, reporting a 93% response rate in its Ultrasome knee osteoarthritis program. Strong clinical results combined with improving price action are starting to bring momentum back to the story. Technical View: 🔸 Tight consolidation with buyers stepping in on dips 🔸 Higher lows forming, showing strength 🔸 Price compressing beneath resistance Key Levels to Watch: 📈 $2.02 🟰 Key support 📈 $2.21–$2.51 🟰 Current consolidation range 📈 $2.74 🟰 Breakout level 📈 $3.08–$3.34 🟰 Major resistance zone 📈 $3.86 🟰 High timeframe resistance With strong clinical momentum and multiple catalysts ahead, CELZ is targeting $100B+ markets, positioning itself for increased attention as the story continues to unfold. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $CYCN $DYAI $MBRX $AIXC

0 · Reply

Market Cap	27.15M
Revenue (ttm)	3.09M
Net Income (ttm)	-7.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-238.19%
Debt to Equity Ratio	0.00

Volume	345,700
Avg Vol	85,268
Day's Range	N/A - N/A
Shares Out	36.44M
Stochastic %K	44%
Beta	1.18
Analysts	Strong Sell
Price Target	$6.00